year 16, Issue 4 (July - August 2022)                   Iran J Med Microbiol 2022, 16(4): 288-295 | Back to browse issues page


XML Persian Abstract Print


1- Department of Infectious Diseases, Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
2- Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3- Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
4- Department of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran
5- Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran , uyahyapoor@yahoo.com
Abstract:   (2678 Views)

Background and Objective: Hepatitis A virus (HAV) and hepatitis E virus (HEV) are both transmitted by the fecal-oral route and are known as leading causes of acute viral hepatitis in the world, especially in developing countries. There is a lack of updated data on HAV and HEV seroprevalence in the north of Iran. This study aimed to determine the seroprevalence of HAV and HEV among blood donors in Babol, Iran.
Methods: A cross-sectional study was performed in 2018 on 491 blood donors referred to the Babol Blood Transfusion Center. The serum samples were tested for anti-HAV and anti-HEV IgG using the enzyme-linked immunosorbent assay (ELISA).
Results: The mean age of blood donors was 40.92 ± 9.86 years. An anti-HAV antibody was found in 385 (78.4%), and an anti-HEV antibody was detected in 8 (1.6%) blood donors. The seroprevalence of HAV was a significant correlation to age, marital and educational status (P<0.001). But there was no significant correlation between anti-HEV and all of our study's information factors (P>0.05).
Conclusion: This study showed that the incidence of HAV in the age group of <33 years is low, and the incidence of HEV has not changed compared to the past and HEV was lower than in other regions in Iran, and it needs more investigation in the north of Iran to obtain detailed information in anti-HEV seroprevalence.

Full-Text [PDF 1246 kb]   (610 Downloads) |   |   Full-Text (HTML)  (741 Views)  
Type of Study: Original Research Article | Subject: Medical Virology
Received: 2021/11/29 | Accepted: 2022/02/15 | ePublished: 2022/05/25

References
1. Bernal W, Smith HM, Williams R. A community prevalence study of antibodies to hepatitis A and E in inner-city London. J Med Virol. 1996;49(3):230-4. [DOI:10.1002/(SICI)1096-9071(199607)49:33.0.CO;2-G]
2. Drexler JF, Corman VM, Lukashev AN, van den Brand JM, Gmyl AP, Brunink S, et al. Evolutionary origins of hepatitis A virus in small mammals. Proc Natl Acad Sci U S A. 2015;112(49):15190-5. [DOI:10.1073/pnas.1516992112] [PMID] [PMCID]
3. Xing L, Li TC, Mayazaki N, Simon MN, Wall JS, Moore M, et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J Biol Chem. 2010;285(43):33175-83. [DOI:10.1074/jbc.M110.106336] [PMID] [PMCID]
4. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol. 2008;48(3):494-503. [DOI:10.1016/j.jhep.2007.12.008] [PMID]
5. Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med. 1985;313(17):1059-67. [DOI:10.1056/NEJM198510243131706] [PMID]
6. Gallian P, Piquet Y, Assal A, Djoudi R, Chiaroni J, Izopet J, et al. [Hepatitis E virus: Blood transfusion implications]. Transfus Clin Biol. 2014;21(4-5):173-7. [DOI:10.1016/j.tracli.2014.07.007] [PMID]
7. Lee EJ, Kwon SY, Seo TH, Yun HS, Cho HS, Kim BK, et al. [Clinical features of acute hepatitis A in recent two years]. Korean J Gastroenterol. 2008;52(5):298-303.
8. Risalde MA, Rivero-Juarez A, Romero-Palomo F, Frias M, Lopez-Lopez P, Cano-Terriza D, et al. Persistence of hepatitis E virus in the liver of non-viremic naturally infected wild boar. PLoS ONE. 2017;12(11):e0186858. [DOI:10.1371/journal.pone.0186858] [PMID] [PMCID]
9. Belei O, Ancusa O, Mara A, Olariu L, Amaricai E, Folescu R, et al. Current Paradigm of Hepatitis E Virus Among Pediatric and Adult Patients. Front Pediatr. 2021;9(1032):721918. [DOI:10.3389/fped.2021.721918] [PMID] [PMCID]
10. Webb GW, Kelly S, Dalton HR. Hepatitis A and Hepatitis E: Clinical and Epidemiological Features, Diagnosis, Treatment, and Prevention. Clin Microbiol Newsl. 2020;42(21):171-9. [DOI:10.1016/j.clinmicnews.2020.10.001] [PMID] [PMCID]
11. Haeri Mazanderani A, Motaze NV, McCarthy K, Suchard M, du Plessis NM. Hepatitis A virus seroprevalence in South Africa - Estimates using routine laboratory data, 2005-2015. PLoS ONE. 2019;14(6):e0216033. [DOI:10.1371/journal.pone.0216033] [PMID] [PMCID]
12. Kamar N, Bendall R, Legrand-Abravanel F, Xia N-S, Ijaz S, Izopet J, et al. Hepatitis E. Lancet. 2012;379(9835):2477-88. [DOI:10.1016/S0140-6736(11)61849-7]
13. Ndumbi P, Freidl GS, Williams CJ, Mardh O, Varela C, Avellon A, et al. Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European :union: and European Economic Area, June 2016 to May 2017. Euro Surveill. 2018;23(33).
14. Khuroo MS, Khuroo MS, Khuroo NS. Transmission of Hepatitis E Virus in Developing Countries. Viruses. 2016;8(9):253. [DOI:10.3390/v8090253] [PMID] [PMCID]
15. Hesamizadeh K, Sharafi H, Keyvani H, Alavian SM, Najafi-Tireh Shabankareh A, Sharifi Olyaie R, et al. Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran. Hepat Mon. 2016;16(1):e32215. [DOI:10.5812/hepatmon.32215]
16. Hoseini SG, Kelishadi R, Ataei B, Yaran M, Motlagh ME, Ardalan G, et al. Seroprevalence of hepatitis A in Iranian adolescents: is it time to introduce a vaccine? Epidemiol Infect. 2016;144(2):291-6. [DOI:10.1017/S0950268815001302] [PMID]
17. Izadi M, Esfahani AA, Hassannia H, Jafari NJ, Najarkolaei FR, Rezaee-Zavareh MS. Seroprevalence of hepatitis A virus among Iranian soldiers. Gastroenterol Hepatol Bed Bench. 2016;9(2):100.
18. Behzadifar M, Lankarani KB, Abdi S, Taheri Mirghaed M, Beyranvand G, Keshavarzi A, et al. Seroprevalence of Hepatitis E Virus in Iran: A Systematic Review and Meta-analysis. Middle East J Dig Dis. 2016;8(3):189-200. [DOI:10.15171/mejdd.2016.31] [PMID] [PMCID]
19. Alavian SM. Occult hepatitis B virus infection among hemodialysis patients. Hepat Mon. 2012;12(4):242-3. https://doi.org/10.5812/hepatmon.869 [DOI:10.5812/hepatmon.6226] [PMID] [PMCID]
20. Ghasemian R, Babamahmoodi F, Ahangarkani F. Hepatitis A Is a Health Hazard for Iranian Pilgrims Who Go to Holly Karbala: A Preliminary Report. Hepat Mon. 2016;16(6):e38138. [DOI:10.5812/hepatmon.38138] [PMID] [PMCID]
21. Alian S, Ajami A, Ghasemian R, Yadegarinia D. Age-specific seroprevalence of hepatitis A in Sari, northern Islamic Republic of Iran. East Mediterr Health J. 2011;17(10):754-8. [DOI:10.26719/2011.17.10.754] [PMID]
22. Saffar MJ, Farhadi R, Ajami A, Khalilian AR, Babamahmodi F, Saffar H. Seroepidemiology of hepatitis E virus infection in 2-25-year-olds in Sari district, Islamic Republic of Iran. East Mediterr Health J. 2009;15(1):136-42. [DOI:10.26719/2009.15.1.136] [PMID]
23. Tahamtan A, Moradi A, Ghaemi A, Kelishadi M, Ghafari H, Hashemi P, et al. Seroepidemiology of Hepatitis E Virus in hemodialysis patients in Gorgan-Iran. Med Lab J. 2013;7(2):13-7.
24. Merat S, Rezvan H, Nouraie M, Abolghasemi H, Jamali R, Amini-Kafiabad S, et al. Seroprevalence and risk factors of hepatitis A virus infection in Iran: a population based study. Arch Iran Med. 2010;13(2):99-104.
25. Mohebbi SR, Rostami Nejad M, Tahaei SM, Pourhoseingholi MA, Habibi M, Azimzadeh P, et al. Seroepidemiology of hepatitis A and E virus infections in Tehran, Iran: a population based study. Trans R Soc Trop Med Hyg. 2012;106(9):528-31. [DOI:10.1016/j.trstmh.2012.05.013] [PMID]
26. Elikaei A, Sharifi Z, Shooshtari MM, Hosseini M, Maroufi Y. Prevalence of HAV among healthy blood donors referring to Tehran transfusion center. Iran J Public Health. 2008;37(4):126-30.
27. Ramezani H, Bozorgi S, Nooranipour M, Mostajeri A, Kargar-Fard H, Molaverdikhani S, et al. Prevalence and risk factors of hepatitis A among blood donors in Qazvin, central Iran. Singapore Med J. 2011;52(2):107-12.
28. Assarehzadegan MA, Shakerinejad G, Amini A, Rezaee SA. Seroprevalence of hepatitis E virus in blood donors in Khuzestan Province, southwest Iran. Int J Infect Dis. 2008;12(4):387-90. [DOI:10.1016/j.ijid.2007.09.015] [PMID]
29. Aminiafshar S, Alimagham M, Gachkar L, Yousefi F, Attarchi Z. Anti hepatitis E virus seropositivity in a group of blood donors. Iran J Public Health. 2004;33(4):53-6.
30. Taremi M, Gachkar L, MahmoudArabi S, Kheradpezhouh M, Khoshbaten M. Prevalence of antibodies to hepatitis E virus among male blood donors in Tabriz, Islamic Republic of Iran. East Mediterr Health J. 2007;13:98-102.
31. Ehteram H, Ramezani A, Eslamifar A, Sofian M, Banifazl M, Ghassemi S, et al. Seroprevalence of Hepatitis E Virus infection among volunteer blood donors in central province of Iran in 2012. Iran J Microbiol. 2013;5(2):172.
32. Johargy AK, Mahomed MF, Khan MM, Kabrah S. Anti hepatitis E virus seropositivity in a group of male blood donors in Makkah, Saudi Arabia. J Pak Med Assoc. 2013;63(2):185-9.
33. Petrovic T, Lupulovic D, Jimenez de Oya N, Vojvodic S, Blazquez AB, Escribano-Romero E, et al. Prevalence of hepatitis E virus (HEV) antibodies in Serbian blood donors. J Infect Dev Ctries. 2014;8(10):1322-7. [DOI:10.3855/jidc.4369] [PMID]
34. Koroglu M, Jacobsen KH, Demiray T, Ozbek A, Erkorkmaz U, Altindis M. Socioeconomic indicators are strong predictors of hepatitis A seroprevalence rates in the Middle East and North Africa. J Infect Public Health. 2017;10(5):513-7. [DOI:10.1016/j.jiph.2016.09.020] [PMID]
35. Cardenas A, Smit E, Bethel JW, Houseman EA, Kile ML. Arsenic exposure and the seroprevalence of total hepatitis A antibodies in the US population: NHANES, 2003-2012. Epidemiol Infect. 2016;144(8):1641-51. [DOI:10.1017/S0950268815003088] [PMID] [PMCID]
36. Carrillo-Santisteve P, Tavoschi L, Severi E, Bonfigli S, Edelstein M, Bystrom E, et al. Seroprevalence and susceptibility to hepatitis A in the European :union: and European Economic Area: a systematic review. Lancet Infect Dis. 2017;17(10):e306-e19. [DOI:10.1016/S1473-3099(17)30392-4]
37. Khojah A, Felimban R, Kabrah S, Alqasmi M. Prevalence of Kell Blood Group System in Blood Donors of Makkah City, Saudi Arabia. Clin Lab. 2021;67(6). [DOI:10.7754/Clin.Lab.2020.200946]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.